
    
      The primary objectives of the study are to provide additional safety data regarding FTC/TDF
      (Truvada®) use as PrEP in YMSM, to examine acceptability, patterns of use, rates of
      adherence, measure levels of drug exposure and patterns of risk behavior when YMSM are
      provided open label FTC/TDF (Truvada®). The study will also examine information regarding
      safety and efficacy of FTC/TDF (Truvada®) as PrEP from prior studies.
    
  